8th Annual Psychopharmacology Update 2022

Join us for the live Psychopharmacology Update 2022, which will be presented online in a live virtual format. Now in its eighth year, this free comprehensive 2-day conference will explore the latest advances in the pharmacotherapy of psychiatric illness. Register early to secure your seat!

To Register: On the Event Dates page, click Webinar/online. On the next screen, please click the blue Register button in the upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the event. Credit for this activity may only be claimed once.


*Subject to change

All times are in Eastern Time

Day 1 – Friday  December 2

9:55 AM - 10:00 AM - Opening Remarks by Moderator - Joseph F. Goldberg, MD

10:00 AM - 11:00 AM - Practical Treatment Strategies for Patients With Tardive Dyskinesia - Leslie Citrome, MD, MPH

Tardive dyskinesia can pose a massive burden to patients and caregivers; aside from prevention, early identification and treatment initiation are key to improving outcomes. This session will provide strategies for preventing and managing tardive dyskinesia in clinical practice, including discussion of the mechanism of action of available treatment options and how to best incorporate them into patient treatment plans.

11:00 AM - 11:05 AM - Break (5 min)

11:05 AM - 12:05 PM - Non-CME Educational Talk
Sponsored by Intra-Cellular Therapies, Inc.
Clinical Case and CAPLYTA: Diagnosis and Management of Bipolar Depression (Bipolar I and II) 
Presenter: Roueen Rafeyan, MD, DFAPA, FASAM

12:05 PM - 12:10 PM - Break (5 min)

12:10 PM - 1:10 PM - Clinical Pearls: Medications for Opioid Use Disorder - Michael Weaver, MD, DFASAM

Opioid use disorder is of growing prevalence in the United States and healthcare providers need to be aware of the available medications for addiction treatment. This session will review the mechanisms of action of buprenorphine, naltrexone, and methadone as they apply to medication-assisted treatment. Learners will also be provided with clinical pearls for taking patient-specific factors into account when choosing, initiating, and following up with treatment.

1:10 PM - 1:40 PM - Break (30 min)

1:40 PM - 2:40 PM - Non-CME Educational Talk
Sponsored by Acadia Pharmaceuticals Inc.
A Case of Parkinson's Disease Psychosis: Managing Hallucinations and Delusions Associated With Parkinson's Disease Psychosis
Presenter: Gustavo Alva, MD, DFAPA

2:40 PM - 2:45 PM - Break (5 min)

2:45 PM - 3:45 PM - Back to Basics: Clozapine - Robert O. Cotes, MD

Despite being the only treatment that is FDA approved for treatment-resistant schizophrenia, clozapine remains highly underutilized in the United States. This session will provide learners with practical tips for how to identify clozapine candidates, initiate clozapine, and manage its side effects. The evidence for pharmacologic strategies for those who have a clozapine partial response will also be discussed.

3:45 PM - 4:00 PM - Break (15 min, including 5-min yoga session)

4:00 PM - 5:00 PM - Tailoring Individualized Pharmacotherapy for Bipolar Disorder: How to Use Moderators and Mediators in Clinical Practice - Joseph F. Goldberg, MD

When individualizing care for patients with bipolar disorder, it's important to take moderators and mediators into account. This session will define the concepts of moderators and mediators and explain how they impact treatment choices and care plans for patients with bipolar disorder.

5:00 PM - 5:05 PM - Break (5 min)

5:05 PM - 6:05 PM - Improving Outcomes in Major Depression: Focus on Individualizing Treatment - Greg W. Mattingly, MD

We now have many options for treatment major depression, but how do we sift through these options to find the optimal agent for each individual patient? This session will shed light on the available and emerging drug classes for major depression, including discussion of adverse event profiles, mechanism of action, and key trials demonstrating their safety and efficacy. In addition to medication characteristics, guidance will be given on patient characteristics to consider when creating a treatment plan for major depression.

6:05 PM - 6:10 PM - Closing Remarks - Joseph F. Goldberg, MD


Day 2 – Saturday  December 3

9:55 AM - 10:00 AM - Opening Remarks by Moderator - Jonathan M. Meyer, MD

10:00 AM - 11:00 AM - Changing Minds, Changing Lives: Elucidating the Role of LAIs - Leslie Citrome, MD, MPH

Long-acting injectable antipsychotics can serve as a tool to enhance medication adherence, reduce relapses, and optimize patient outcomes in schizophrenia and bipolar I disorder. However, one of the largest barriers to their uptake in clinical practice relates to patient perceptions of stigma associated with injectable medications. This session will review the available and emerging LAI antipsychotics and provide attendees with valuable communication strategies to help reduce stigma associated with LAIs and establish a trusting patient-provider relationship. 

11:00 AM - 11:05 AM - Break (5 min)

11:05 AM - 12:05 PM - Non-CME Educational Talk
Sponsored by Neurocrine Biosciences, Inc.
Know the Difference to Make a Difference: Tardive Dyskinesia vs Drug-Induced Parkinsonism
Presenter: Jonathan M. Meyer, MD

12:05 PM - 12:10 PM - Break (5 min)

12:10 PM - 1:10 PM - Clinical Pearls: Bipolar Depression - Joseph F. Goldberg, MD

Bipolar disorder exists as a spectrum, making it imperative that healthcare professionals be able to develop treatment plans specific to each patient’s symptoms, presentation, and needs. This session will inform learners of the available and emerging pharmacotherapies for bipolar depression, along with clinical pearls for incorporating them into individualized treatment plans.

1:10 PM - 1:40 PM - Break (30 min)

1:40 PM - 2:40 PM - Non-CME Educational Talk
Sponsored by Janssen Pharmaceuticals, Inc.
Coordination of Care Between Referring Psychiatrist and Treatment Center Provider 
Presenters: Chester Robachinski, MD and Sandhya Prashad, MD 

2:40 PM - 2:45 PM - Break (5 min)

2:45 PM - 3:45 PM - Complex But Not Complicated: Diagnosis and Treatment of ADHD With Comorbidities - Vladimir Maletic, MD

People with ADHD often have psychiatric or other comorbidities that can make management complex. This session will provide information on diagnosing and managing ADHD in the presence of common comorbid conditions—such as substance use disorder, bipolar disorder, anxiety, and depression.

3:45 PM - 4:00 PM - Break (15 min, including 5-min yoga session)

4:00 PM - 5:00 PM - New and Emerging Agents for Schizophrenia - Jonathan M. Meyer, MD

Schizophrenia is estimated to affect 0.25% to 0.64% of the population in the United States. Although antipsychotics generally have demonstrable efficacy for decreasing risk of relapse and readmission, 75% of patients will discontinue their antipsychotic within 18 months. This session will review current and novel treatment options, their efficacy and safety, adverse events, and monitoring recommendations to ensure appropriate treatment is provided and to promote patient adherence.

5:00 PM - 5:05 PM - Break (5 min)

5:05 PM - 6:05 PM - Back to Basics: Antidepressants - Anita Clayton, MD

This session will discuss assessment of mood and anxiety disorders, including major depressive disorder, bipolar disorder, persistent depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, posttraumatic disorder, and social phobia, as well as common comorbidities. Dr Clayton will also review how to develop a treatment plan that addresses the primary condition and comorbidities with the fewest medications while considering patient preferences and potential adverse events, recognizing when augmentation strategies are indicated, and discontinuing substances/medications that cause or maintain symptoms.

6:05 PM - 6:10 PM - Closing Remarks - Jonathan M. Meyer, MD


Date / Time
Event Details


Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Anita Clayton, MD

David C. Wilson Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
University of Virginia School of Medicine
Charlottesville, Virginia

Robert O. Cotes, MD

Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Joseph F. Goldberg, MD

Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Vladimir Maletic, MD

Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

Greg W. Mattingly, MD

Associate Clinical Professor
Washington University School of Medicine
St Louis, Missouri
St Charles Psychiatry Associates
St Charles, Missouri

Jonathan M. Meyer, MD

Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Michael Weaver, MD

Department of Psychiatry and Behavioral Sciences
Medical Director
Center for Neurobehavioral Research on Addiction
McGovern Medical School
University of Texas Health Science Center at Houston
Houston, Texas

Program Overview
This program will arm healthcare professionals with valuable information regarding available and emerging pharmacologic agents for use in psychiatry practice. From drug mechanism of action to dose adjustments to factors to consider when developing individualized treatment plans, this 2-day event aims to help optimize patient outcomes in psychiatry.

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of psychiatric illness.

Target Audience
This activity is intended for physicians, physician associates/physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with psychiatric illness.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patient factors to consider when choosing pharmacologic agents for psychiatric disorders
  • Discuss emerging evidence and innovations in psychopharmacology as it relates to the treatment of psychiatric disorders
  • Develop strategies to individualize treatment plans and optimize outcomes in patients with psychiatric disorders


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity will be 10.0 contact hours.

This educational activity for 10.0 contact hours, including 10.0 hours of pharmacology credit is provided by Clinical Care Options, LLC.

Continuing Pharmacy Education

CCO designates this continuing education activity for 10.0 contact hours (1.0 CEUs) of the Accreditation Council for Pharmacy Education. UAN: UAN will be specific to each topic

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Psychologist Continuing Education

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity will offer 10.0 continuing education credits for psychologists

Social Work Continuing Education

As a Jointly Accredited Organization, Clinical Care Options, LLC (CCO) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CCO maintains responsibility for this course. Social workers completing this course will receive 10.0 continuing education credits.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.